UCB Pharma and HOPOS join the Rare Disease Action Forum

    10 Jan, 2022

    We are proud to welcome UCB Pharma and HOPOS as the newest members of the Rare Disease Action Forum. Reinforcing RDAF’s multi-stakeholder approach, they will be joining our other members including industry, patient organizations, healthcare professionals, and research organizations. We look forward to their contribution to the collaborative efforts at the RDAF multi-stakeholder platform. Together we will continue our efforts to improve access to diagnosis, treatment and care for patients with rare diseases in Switzerland.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...